Catriona Yale - Oct 15, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Development Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Stock symbol: AKRO
Transactions as of: Oct 15, 2021
Transactions value $: -$269,826
Form type: 4
Date filed: 10/18/2021, 04:21 PM
Previous filing: Sep 17, 2021
Next filing: Dec 10, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Sale	-$268K	-12.4K	-9.29%	$21.58	121K	Oct 15, 2021	Direct	F1, F2
transaction	AKRO	Common Stock	Sale	-$2.23K	-100	-0.08%	$22.34	121K	Oct 15, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2020, as amended on June 11, 2021, previously adopted by the reporting person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $22.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2020, as amended on June 11, 2021, previously adopted by the reporting person.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $22.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.